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Abstract
Background: Omega (n)-3 polyunsaturated fatty acids (PUFA) are converted to bioactive lipid components that are
important mediators in metabolic and physiological pathways; however, which bioactive compounds are metabolically
active, and their mechanisms of action are still not clear. We investigated using lipidomic techniques, the effects of
diets high in n-3 PUFA on the fatty acid composition of various bioactive lipids in plasma and liver.
Methodology and Principal Findings: Female C57BL/6 mice were fed semi-purified diets (20% w/w fat) containing
varying amounts of n-3 PUFA before mating, during gestation and lactation, and until weaning. Male offspring were
continued on their mothers’ diets for 16 weeks. Hepatic and plasma lipids were extracted in the presence of non-
naturally occurring internal standards, and tandem electrospray ionization mass spectrometry methods were used to
measure the fatty acyl compositions. There was no significant difference in total concentrations of phospholipids in
both groups. However, there was a significantly higher concentration of eicosapentaenoic acid containing
phosphatidylcholine (PC), lysophosphatidylcholine (LPC), and cholesteryl esters (CE) (p < 0.01) in the high n-3
PUFA group compared to the low n-3 PUFA group in both liver and plasma. Plasma and liver from the high n-3 PUFA
group also had a higher concentration of free n-3 PUFA (p < 0.05). There were no significant differences in plasma
concentrations of different fatty acyl species of phosphatidylethanolamine, triglycerides, sphingomyelin and
ceramides.
Conclusions/Significance: Our findings reveal for the first time that a diet high in n-3 PUFA caused enrichment of
n-3 PUFA in PC, LPC, CE and free fatty acids in the plasma and liver of C57BL/6 mice. PC, LPC, and unesterified
free n-3 PUFA are important bioactive lipids, thus altering their fatty acyl composition will have important metabolic
and physiological roles.
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Introduction
Essential polyunsaturated fatty acids (PUFA) of the omega-3
(n-3) and n-6 classes are important in the regulation of
metabolic processes. N-3 PUFA such as docosahexaenoic
acid (DHA; 22:6) and eicosapentaenoic acid (EPA; 20:5) have
attracted a lot of attention in the past years as a result of their
potential health benefits [1-3]. N-3 PUFA has been shown to
prevent atherosclerosis [4,5], regulate nuclear transcription
factors involved in gene expression of inflammatory markers,
and stimulate cognitive development [6,7]. Markers of
cardiovascular disease such as high triglycerides (TG),
endothelial dysfunction, cardiac arrhythmia, and inflammation
are also reduced by the administration of n-3 PUFA [1,8-11].
In vivo¸ n-3 PUFA can either exist as free products of
enzyme hydrolysis or bound to phospholipids (PL) or TG.
Reports have shown that dietary n-3 PUFA are preferentially
incorporated into PL compared to TG [12]. PL are important
constituents of the cellular membrane bilayer, with
phosphatidylcholine (PC) and phosphatidylethanolamine (PE)
being the most abundant [13]. Membrane fluidity can be
influenced by the incorporation of dietary long chain n-3 PUFA
into membrane PL, which enhances the functions of
transmembrane proteins and their interactions with
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extracellular ligands [14-16]. This indirectly affects signalling
pathways and other physiological functions of the membrane.
PC has been implicated in an array of physiological functions,
and their functional properties depend on their fatty acyl chains.
The liver is principally involved in the metabolism and
release of PC into circulation. PC is metabolized by the
enzyme phospholipase A2 releasing the fatty acid at the sn-2
position, and lysophosphatidylcholine (LPC) into the plasma
pool for distribution to extrahepatic tissues [17,18]. Upon
hydrolysis of the sn-2 fatty acid of PC, the released free fatty
acids (FFA) are further metabolized to form bioactive
compounds with either pro-inflammatory or anti-inflammatory
properties [18]. Arachidonic acid (AA; 20:4), a long chain n-6
PUFA released from the metabolism of PC, is further
metabolized by the cyclooxygenase or lipoxygenase enzyme
pathways to produce the inflammatory series-2 prostaglandins
or series-4 leukotrienes, respectively [19]. On the contrary, the
cyclooxygenase and lipoxygenase metabolic products of EPA,
an n-3 PUFA, are generally anti-inflammatory [20].
Furthermore, protectins and resolvins, the products of
oxygenation of DHA and EPA, have been reported to exhibit
anti-inflammatory properties [21-23].
LPC, the other product of enzyme hydrolysis of PC, is an
important lipid mediator involved in cellular metabolism. Direct
hepatic secretion is an important source of the abundant
unsaturated LPC found in the plasma [24]. LPC has been
controversially linked with the development of atherosclerosis
[25-27]. However, there are burgeoning evidences suggesting
that the biological properties of LPC depend on the acyl chain
of the molecule [28,29]. Studies have reported an increase in
plasma concentration of saturated LPC in diseases conditions
such as obesity, diabetes and rheumatoid arthritis [30]. In
another line of evidence, polyunsaturated LPC significantly
reversed saturated LPC induced inflammation [31]. However,
the importance of specific LPC fatty acyl chain in metabolic
regulation is still not clear.
Most studies to date have explored the health benefits of n-3
PUFA esterified to ethyl esters or TG [32-34]. Moreover, the
majority of the reported findings that support the pro-
inflammatory and the atherogenic actions of LPC were
established using saturated or monounsaturated LPC
[25,26,35-37]. Cells, tissues, and biological fluids consist of
numerous bioactive lipid mediators involved in cellular
processes, which are likely altered by dietary n-3 PUFA. The
aim of this study was to employ high throughput lipidomic
techniques to evaluate the effect of diets high or low in n-3
PUFA content on the fatty acid composition of various lipids in
the plasma and liver of C57BL/6 mice. Our findings reveal for
the first time that diets high in n-3 PUFA caused enrichment of
n-3 PUFA in PC, LPC, cholesteryl esters (CE) and FFA in the
plasma and liver of C57BL/6 mice, which will likely have
important physiological roles.
Materials and Methods
Ethics statement
All experimental procedures were approved by Memorial
University Animal Care Committee in accordance with the
principles and guidelines of Canadian Council on Animal Care
(approval no: 10-09-SK).
Animals and diets
Seven week old male and female C57BL/6 mice were
purchased from Charles River Laboratories (MA, USA), and
were housed in separate cages under controlled temperature
(21± 1°C) and humidity (35 ± 5%) conditions with a 12-hour
light/12-hour dark period cycle. Mice were kept on standard
rodent chow pellets (Prolab RMH 3000) purchased from PMI
nutrition (MO, USA) for one week acclimatization period. After
this period, female mice were randomly divided into two
groups. Each group was fed either of the two experimental
diets that differed only in their n-3 PUFA composition, and
designated as “high n-3” and “low n-3” diets for two weeks
before mating. The experimental diets were made from a base
semi-synthetic diet (MP Biomedicals, OH, USA), which allows
for the control of fat level at 20% w/w. Menhaden oil was
obtained from Sigma-Aldrich (MO, USA); lard, safflower oil and
extra-virgin olive oil were used to prepare two different oil
mixtures containing 10% (high n-3) and 2% (low n-3) n-3 PUFA
of the total fat, giving an n-6 to n-3 PUFA ratio of 5:1 and 30:1
respectively. The fatty acid composition of the diets was
analyzed by gas chromatography as per our previous
publication [38] and is given in Table 1. Females were
continued on the experimental diets throughout gestation,
lactation, and until weaning. Just before weaning, breast milk
samples were collected from the mothers, to ascertain that the
dietary essential fatty acid is reflected in the breast milk. There
was a positive correlation between dietary and breast milk fatty
acids composition (data not shown). At weaning, male offspring
(n=6) were continued on their mothers’ designated diet for 16
weeks (i.e. offspring obtained from mother’s fed a high n-3
PUFA diet continued on high n-3 PUFA diet). Only male
offspring were used in this study in order to prevent hormonal
interference. Female sex hormones have been shown to affect
tissue plasma and tissue n-3 PUFA content [39]; and it is well
known that there is gender specificity in lipid metabolism,
possibly due to the effect of hormonal differences [39-42].
Animals were provided with water and fresh food ad libitum,
every other day. Body weights were recorded once a week,
and food intake was recorded every other day. No significant
differences were observed in both body weight and food intake
(Table S1 in File S1). At 16 weeks, male offspring were fasted
overnight and sacrificed using isoflurane. Blood was collected
by cardiac puncture in tubes containing EDTA (4.5 mM, pH
7.4), and plasma was separated immediately. Tissues were
removed and weighed at the time of sacrifice, snap frozen in
liquid nitrogen and stored at -80°C until further analyses.
Lipidomic analysis
Lipid extraction, standards, and solvents.  Plasma or liver
samples were flash frozen at the temperature of liquid nitrogen
at collection. 10 µl plasma was directly extracted into organic
solvent, while 100 mg liver tissue was pulverized and
homogenized and then immediately lipids were extracted into
organic solvent. Lipid extraction into organic solvent was
performed using the Bligh-Dyer method [43] with high
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performance liquid chromatography-mass spectrometry grade
solvents in the presence of non-naturally occurring internal lipid
standards. The standards used were Δ9-trans-triheptadecenoin
(tri-17:1 TG), 1, 2-diarachidoyl-sn-glycero-3-phosphocholine
(di-20:0 PC), N-heptadecanoyl-D-erythro-
sphingosylphosphorylcholine (17:0 sphingomyelin), 1-
heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine (17:0
LPC), 1, 2-dimyristoyl-sn-glycero-3-phosphoethanolamine
(di-14:0 PE), cholesteryl heptadecanoate (17:0 CE), and N-
hepadecanoyl-D-erythro-sphingosine (17:0 ceramide). The
extracted lipids in the chloroform phase were dried down under
gentle stream of N2 gas, and re-suspended in 500 µl of
chloroform. 50 µl aliquot of the suspension was then mixed with
200µl methanol and 2µl of 10 mM methanolic NaOH and
injected into a Thermo Fisher TSQ Quantum Ultra tandem
electrospray ionization mass spectrometry (ESI-MS) system for
lipid analyses. High pressure liquid chromatography-mass
spectrometry grade methanol and chloroform were used for all
extractions; these solvents were purchased from Burdick and
Jackson (NJ, USA).
Electrospray ionization-mass spectrometry (ESI-
MS).  Samples were analysed using direct-infusion ESI-MS in
positive or negative ion mode using a Thermo Fisher TSQ
Quantum Ultra system with XCalibur data acquisition software
[44]. The tune parameters for sample analyses were optimized
Table 1. Fatty acid composition of the experimental diets.
Fatty Acid High n-3 Low n-3
C14:0 1.26 0.11
C16:0 8.71 6.32
C18:0 2.67 5.35
ΣSFA 12.64 11.77
C16:1n7 2.41 0.36
C18:1n9 + C18:1n7 25.14 27.82
C20:1n9 0.61 ND
ΣMUFA 28.16 28.18
C18:2n6 47.86 57.73
C20:4n6 0.23 0.11
C18:3n6 0.10 0.04
C22:4n6 0.54 0.09
ΣOmega-6 48.90 57.92
C18:3n3 0.78 0.55
C20:5n3 3.64 0.31
C22:6n3 3.19 0.39
C18:4n3 0.87 0.15
C22:5n3 0.63 0.46
C20:4n3 0.66 0.08
ΣOmega-3 9.76 1.93
ΣPUFA 59.38 60.00
ΣOmega-6/Omega-3 5.00 30.01
Lipids were extracted from the diets and the fatty acid composition was determined
by gas chromatography. Values are given as % area of each fatty acid peak.
Abbreviations: ND= Not detected, ΣSFA= sum of saturated fatty acids, ΣMUFA=
sum of monounsaturated fatty acids, Σ PUFA= sum of polyunsaturated fatty acids,
ΣOmega-6= sum of omega-6 fatty acids, ΣOmega-3= sum of omega-3 fatty acid.
doi: 10.1371/journal.pone.0082399.t001
and set as follows: spray voltage = 3500 V, flow rate = 3 µl/min,
ion sweep gas pressure = 0.2 (arbitrary units), sheath gas = 12
(arbitrary units), auxiliary gas pressure = 6 (arbitrary units), and
capillary temperature = 270°C. The collision energies for the
analyses of PC, LPC, and sphingomyelins (SM) were set at 28
eV. The collision energies for analyses of cholesteryl esters
(CE) was set at 25 eV, and for ceramide (CER) was set at 32
eV. CEs were detected in positive ion mode by scanning for
neutral loss (NL) of cholestadane (m/z 368.5). Sodiated
species of SM, PC, and LPC were detected in positive ion
mode by scanning for the NL of choline (m/z 59.1). FFA and
PE were identified in negative ion mode by survey scan for [M-
H] - between m/z 200 and 900. Sodiated species of TG were
identified in positive ion mode by survey scan for [M+Na]+
between m/z 800 and 1000. All data analyzed were corrected
for 13C isotope effects as described by Han et al. [44].
Statistical analysis
Data were analysed using GraphPad Prism software (version
5.0). Statistical significance for differences between groups
was determined by unpaired t-test. Results are expressed as
mean ± standard deviation (SD). Differences were considered
to be statistically significant if the associated P value was <
0.05.
Results
PC fatty acyl composition of mice fed high and low n-3
PUFA
There were no significant differences in the total
concentrations of phospholipids in both plasma and liver
between high and low n-3 PUFA fed mice (Table S2 in File S1).
However, there was a significantly higher concentration of
16:0-20:5 PC in the plasma (p < 0.01; Figure 1A) and liver (p <
0.05; Figure 1B) of the high n-3 PUFA group compared to the
low n-3 PUFA group. Interestingly, 20:4 containing PC
(16:0-20:4 and 18:0-20:4) increased significantly in the plasma
of the low n-3 PUFA group compared to the high n-3 PUFA
group (p < 0.05; Figure 1A). A similar effect was observed in
the liver, with 16:0-20:4 and 18:0-20:4 showing a significant
increase in the low n-3 PUFA group (p < 0.001; Figure 1B).
This signifies a higher incorporation of EPA and a lower
incorporation of AA into plasma PC in the high n-3 PUFA
group. The high n-3 PUFA group also showed higher
incorporation of DHA into hepatic PC compared to the low n-3
PUFA group (p < 0.05; Figure 1B); however, there were no
differences in plasma DHA containing PC in both groups
(Figure 1A).
FFA of mice fed high and low n-3 PUFA
There was a significant accretion of AA in the plasma of the
low n-3 PUFA group compared to the high n-3 PUFA group (p
< 0.05; Figure 2A). The plasma concentration of EPA was
considerably higher in the high n-3 PUFA group compared to
the low n-3 PUFA group (p < 0.05; Figure 2A). However, no
significant difference was observed in the plasma concentration
of DHA in both groups. Livers of the mice fed a low n-3 PUFA
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Figure 1.  Phosphatidylcholine (PC) fatty acyl composition of mice fed high and low n-3 PUFA enriched diets.  Plasma (A)
and liver (B) PC species were quantified by measuring the sodiated adducts of PC using ESI-MS in positive ion mode by NL
scanning for m/z 59.1, as described in the “Methods”. Data were corrected for 13C isotopic effects. Data are presented as mean
(n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g001
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diet were significantly enriched with 18:1 and 20:4 FFA (p <
0.01; Figure 2B) compared to the high n-3 PUFA group.
Similarly, the liver concentrations of EPA (p < 0.01; Figure 2B)
and DHA (p < 0.05; Figure 2B) were significantly higher in the
high n-3 PUFA group compared to the low n-3 PUFA group.
LPC fatty acyl composition of mice fed high and low
n-3 PUFA
Similar to the PC data, the concentration of 20:5 LPC was
significantly higher in the high n-3 PUFA group compared to
the low n-3 PUFA group, in both plasma (p < 0.01; Figure 3A)
and liver (p < 0.01; Figure 3B). However, there was a
significant accretion of 20:4 LPC in the plasma (p < 0.01;
Figure 3A) and liver (p < 0.05; Figure 3B) of the low n-3 PUFA
group compared to the high n-3 PUFA group. Irrespective of
the differences observed in LPC, there was no significant
difference in the total concentration of LPC in both groups
(Table S2 in File S1).
PE fatty acyl composition of mice fed high and low n-3
PUFA
No significant differences were observed in the fatty acyl
species of PE in the plasma (Figure 4A) of the high n-3 PUFA
and low n-3 PUFA groups. The liver showed no differences
amongst PE species containing EPA; however, there was a
significant increase of hepatic 18:0-22:6 PE in the high n-3
PUFA group compared to the low n-3 PUFA group (p < 0.05;
Figure 4B).
Sphingolipid and ceramide fatty acyl composition of
mice fed high and low n-3 PUFA
Treatment with high n-3 PUFA did not significantly modify the
fatty acyl species of SM in the plasma (Figure 5A) and liver
(Figure 5B) of mice fed diet high in n-3 PUFA. Plasma of mice
from high n-3 PUFA group showed an increase in 16:0 CER
compared to the low n-3 PUFA group (p < 0.05 Figure 6A);
however, there was no effect of diet on different fatty acyl
species of CER in the liver (Figure 6B).
CE and TG fatty acyl composition of mice fed high and
low n-3 PUFA
The high n-3 PUFA group showed a significant increase in
plasma 20:5 CE compared to the low n-3 PUFA group (p <
0.05; Figure 7A). Conversely, there was a high accumulation of
plasma 20:4 CE in the low n-3 PUFA group compared to the
high n-3 PUFA group (p < 0.05; Figure 7A). The liver of the
high n-3 PUFA group was enriched in 20:5 CE (p < 0.001;
Figure 7B) and 22:6 CE (p < 0.01; Figure 7B) compared to the
low n-3 PUFA group. The liver concentration of 20:4 CE was
significantly higher in the low n-3 PUFA group (p < 0.01; Figure
7B) compared to the high n-3 PUFA group.
No differences were observed in the concentrations of the
different fatty acyl species of TG found in the plasma in both
experimental groups (Figure 8A). Nevertheless, the liver
showed a distinctive difference in the concentration of fatty acyl
species profile for TG. The concentrations of 54:6, 56:7, and
58:8 TGs were significantly greater in the high n-3 PUFA group
compared to the low n-3 PUFA group (p < 0.01; Figure 8B).
The low n-3 PUFA group showed a significantly higher 54:3
and 56:5 TG species compared to the high n-3 PUFA group (p
< 0.05; Figure 8B).
Discussion
N-3 PUFA have been shown to reduce plasma TG [8,45],
prevent atherosclerosis [46], and alleviate inflammation [47]. It
has been proposed that the beneficial effects of n-3 PUFA are
mediated through the actions of bioactive lipid components;
however which bioactive lipids are metabolically active, and
their mechanisms of action are still not clear. We performed
lipidomic analyses on plasma and liver samples of high and low
n-3 PUFA fed male C57BL/6 mice. There was an evident
distinction in the fatty acid profiles of different lipids present in
the plasma and liver of the two dietary groups. Feeding a high
n-3 PUFA diet led to a marked reduction of AA containing PC,
with a concomitant increase of EPA containing PC. Although
plasma samples from mice fed a high or low n-3 PUFA diet
showed no difference in DHA containing PC, there was a trend
towards an increase in the high n-3 PUFA group. Browning et
al. reported that habitual supplementation of fish oil led to an
increased incorporation of EPA in plasma PC [48]; however,
they did observe a significant incorporation of DHA into PC
after dietary supplements of DHA [48]. A plausible explanation
for the disparity in our findings is that DHA containing PC is
rapidly converted to LPC for delivery to extrahepatic tissues.
The liver PC fatty acyl composition is consistent with changes
in plasma PC, where high dietary n-3 PUFA increased the
concentrations of hepatic EPA and DHA species of PC. On the
contrary, there was a significant reduction of hepatic AA
containing PC in mice fed high n-3 PUFA diet. PC is an
important phospholipid involved in lipid metabolism. PC has
been shown to play a major role in cellular proliferation,
degeneration, and membrane fluidity and functions [13]. The
physiological properties of PC are heavily dependent on their
fatty acid composition and n-3 PUFA has been shown to be
preferentially incorporated into PC [48]. PC from marine
sources are rich in n-3 PUFA and have been shown to
significantly reduce markers of inflammation [49], by the
inhibition of TNF-α induced activity of NF-κB [50]. In addition to
their anti-inflammatory effects, n-3 PUFA rich PC are also
known to possess lipid lowering effects [51-53].
Plasma PC is rapidly metabolised by phospholipase A2 to
produce FFA and LPC. These bioactive metabolites of PC can
also elicit beneficial effects depending on the type, chain
length, and degree of unsaturation of their fatty acids. Feeding
diets enriched in n-3 PUFA caused an increase in the plasma
concentration of EPA and a decrease in plasma concentration
of AA. PC is an important source of FFA in plasma [48]. We
found a high concentration of EPA containing PC in the high
n-3 PUFA group; it is thus reasonable to assume that the high
plasma concentration of EPA found in the high n-3 PUFA fed
mice is partly a product of enzyme hydrolysis of EPA rich PC.
This is in line with previous findings that support the
incorporation of n-3 PUFA into the plasma pool when given as
dietary supplements [48,54]. We observed that the dietary
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Figure 2.  Free fatty acid (FFA) composition of mice fed high and low n-3 PUFA enriched diets.  Plasma (A) and liver (B) FFA
composition was quantified by measuring [M-H]- using ESI-MS in negative ion mode between m/z 200 and 900. Data were
corrected for 13C isotopic effects. Data are presented as mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05;
**P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g002
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Figure 3.  Lysophosphatidylcholine (LPC) fatty acyl composition of mice fed high and low n-3 PUFA enriched
diets.  Plasma (A) and liver (B) LPC species were quantified by measuring the sodiated adducts of PC using ESI-MS in positive ion
mode by NL scanning for m/z 59.1, as described in the “Methods”. Data were corrected for 13C isotopic effects. Data are presented
as mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g003
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Figure 4.  Phosphatidylethanolamine (PE) fatty acyl composition of mice fed high and low n-3 PUFA enriched
diets.  Plasma (A) and liver (B) levels of PE species were quantified by measuring [M-H]- using ESI-MS in negative ion mode
between m/z 200 and 900. Data were corrected for 13C isotopic effects. Data are presented as mean (n=6) ± SD and P-values
calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g004
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Figure 5.  Sphingomyelin (SM) fatty acyl composition of mice fed high and low n-3 PUFA enriched diets.  Plasma (A) and
liver (B) levels of SM species were quantified by measuring the sodiated adducts of PC using ESI-MS in positive ion mode by NL
scanning for m/z 59.1, as described in the “Methods”. Data were corrected for 13C isotopic effects. Data are presented as mean
(n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g005
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Figure 6.  Ceramide (CER) fatty acyl composition of mice fed high and low n-3 PUFA enriched diets.  Plasma (A) and liver (B)
CER species were quantified using ESI-MS in negative ion mode by NL scanning for m/z 256.2. Data were corrected for 13C isotope
effects. Data are presented as mean (n=6) ± SD and P-values calculated using unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g006
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Figure 7.  Cholesteryl ester (CE) fatty acyl composition of mice fed high and low n-3 PUFA enriched diets.  Plasma (A) and
liver (B) CE species were quantified using ESI-MS in positive ion mode by NL scanning of m/z 368.5 as described in the “Methods”.
Data were corrected for 13C isotope effects. Data are presented as mean (n=6) ± SD and P-values calculated using unpaired t-test.
*P < 0.05; **P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g007
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Figure 8.  Triglyceride (TG) fatty acyl composition of mice fed high and low n-3 PUFA enriched diets.  Plasma (A) and liver
(B) TG species were quantified by measuring [M+Na]+ using ESI-MS in positive ion mode between m/z 800 and 1000 described in
the “Methods”. Data were corrected for 13C isotope effects. Data are presented as mean (n=6) ± SD and P-values calculated using
unpaired t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
doi: 10.1371/journal.pone.0082399.g008
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supplementation with high n-3 PUFA caused an increase in the
concentrations of hepatic EPA and DHA, and a decline in the
hepatic concentration of AA. Our observation is in line with the
study of Lamaziere et al., who reported an increase in hepatic
EPA and DHA after rats were administered fish oil for 30 days
[55]. In addition to the aforementioned health benefits of n-3
PUFA, high hepatic n-3 PUFA are also involved in inhibiting
lipogenesis thereby preventing the development of non-
alcoholic fatty liver disease (NAFLD) [55]. Mechanistically, n-3
PUFA has been shown to regulate lipogenesis by inhibiting
LXR and SREPB-1c [56,57]. Chronic low-grade inflammation
underlies the pathology of most metabolic disorders, and free
n-3 PUFA has been shown to possess potent anti-inflammatory
properties [58]. N-3 PUFA alleviates inflammation by directly
regulating transcription factors involved in inflammation [59-61]
and indirectly by producing series-3 and series-5 eicosanoids
[62,63]. In addition to their inflammation resolving properties,
free unesterified n-3 PUFA have also been shown to improve
symptoms of dyslipidaemia [9-11].
Another important bioactive product of enzyme hydrolysis of
PC is LPC. We found that feeding a diet high in n-3 PUFA
considerably increased plasma circulating levels of 20:5 LPC,
and drastically reduced plasma concentration of 20:4 LPC.
Similar to our plasma data, we found a higher concentration of
hepatic 20:5 LPC and a low concentration of hepatic 20:4 LPC
in the high n-3 group. Interestingly, there was no significant
difference in hepatic 22:6 LPC, although there was a trend
towards an increase in the high n-3 PUFA group. Ottestad et
al. recently reported a similar finding where fish oil
supplementation to healthy humans significantly increased
plasma 20:5 LPC and 22:6 LPC [64]. Another study by Block et
al. also found that fish oil supplementation increased EPA and
DHA containing LPC [65]. However, we only found a change in
plasma EPA containing LPC, while there was no difference in
DHA containing LPC between the two groups. LPC has been
suggested as the major carrier of DHA to the brain tissues [66];
tracer studies revealed that labelled LPC injected into the blood
of rat disappeared within 20 s and were recovered in different
organs including the brain [17]. It would thus be logical to
believe that the DHA containing LPC was rapidly cleared from
circulation.
Studies have controversially linked LPC with the
development of atherosclerosis [25-27]. This is possibly due to
their association with oxidized LDL, and promotion of
inflammation [67,68] by generating reactive oxygen species
and nitric oxides in different types of cells [69,70]. However, the
studies that linked LPC with the pathogenesis of obesity,
diabetes, and rheumatoid arthritis have reported an increase in
saturated LPC [30]. Of paramount importance to the biological
functions of LPC are acyl length and degree of saturation of
their fatty acids [65]. LPC rich in n-3 PUFA have been shown to
possess beneficial properties. N-3 PUFA species of LPC were
found to reduce inflammation [71,72], and LPC containing DHA
at sn-1 position exhibits significantly higher anti-inflammatory
properties compared to LPC with either linoleic or arachidonic
acid [31,73,74]. It has been proposed that LPC containing n-3
PUFA exhibit their anti-inflammatory properties through
hydrolytic cleavage of the n-3 PUFA moiety, or oxygenation by
15-lipooxygenase (15-LOX) to produce inflammation resolving
lipids such as 1-(15-hydroperoxyeicosatetraenoyl)-LPC and 1-
(17- hydroperoxydocosahexaenoyl)-LPC [74]. Most of the
available data on the health benefits of n-3 PUFA rich LPC
were shown using LPC containing n-3 PUFA at sn-1 position.
We have not investigated the position of the acyl group of our
LPC, however, it is known that there is rapid isomerization of
acyl group from sn-2 to a more stable sn-1 position in LPC [75].
It has been reported that after separation of blood from plasma,
90% of the unsaturated fatty acids were found at sn-1 position
in LPC [24]. We can therefore speculate that a significant
percentage of the plasma 20:5 LPC contain EPA at sn-1
position.
Also noteworthy is the fact that, despite the changes in fatty
acyl species of PC and LPC in response to diet, there was no
difference in the total concentrations of PC and LPC between
the two experimental groups. A similar observation was found
by Ottestad et al., where they found no difference in total
concentrations of PC and LPC despite the apparent changes in
individual fatty acyl species in response to fish oil
supplementation [64]. This interesting observation suggests
that the functional properties of n-3 PUFA involve remodelling
and improving the quality of bioactive lipid mediators without
affecting their concentrations.
A diet rich in n-3 PUFA had no effect on different fatty acyl
species of plasma TG, confirming preferential incorporation of
n-3 PUFA into PC. However, the high n-3 PUFA diet led to an
increase in plasma and liver concentrations of n-3 PUFA CE,
and a decrease in 20:4 CE. CE is less polar than free
cholesterol and it functions as an inert storage molecule. The
high incorporation of n-3 PUFA in CE could be explained as a
response to the high n-3 PUFA in the diet. This would simply
indicate that n-3 PUFA are stored and will be later released for
other physiological functions. A cross sectional study has
reported a positive correlation between dietary PUFA and CE
[76].
Although we have shown that there is high incorporation of
n-3 PUFA in the liver and plasma PC and LPC of mice fed high
n-3 diet, it was also imperative to ascertain the effect of high
n-3 PUFA diet on PE, which is also abundant in the
membranes. There was no difference in plasma PE between
the two dietary groups; the only difference detected in the liver
was an increase in 18:0-22:6 PE in the high n-3 group. Our
findings confirm that fish oil supplementation leads to a
preferential incorporation of n-3 PUFA into PC and LPC
compared to other phospholipids [64].
Sphingolipids, such as CER and SM, are important signalling
molecules. CER is a sphingolipid linked with inflammation and
the pathogenesis of cardiovascular diseases (CVD) [77,78].
There are also speculations on the involvement of CER in
insulin signalling, although available information is scanty
[79,80]. We found no difference in total concentration of CER in
plasma and liver. Our findings are similar to Ottestad et al.,
who found that fish oil supplement had no effect on plasma
concentration of CER. Interestingly, we found an increase in
16:0 CER in the high n-3 PUFA group. The functional roles of
this CER species are currently unknown and needs to be
explored. There was no difference in plasma and liver SM
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concentrations between the two groups. The physiological
functions of SM have not been extensively studied. However, it
is known that SM are involved in the formation of specialized
membrane microdomains known as lipid rafts involved in
signalling.
In conclusion, our findings have shown that diets high in n-3
PUFA alter plasma and liver lipidomic profile of the offspring.
We found that n-3 PUFA is preferentially incorporated into PC
and LPC, and despite the changes in lipidomic profile, the total
concentrations of these lipids were not altered. Additionally, we
found that dietary n-3 PUFA is capable of remodelling the fatty
acyl moieties of PC, LPC, and CE, which may have important
physiological implications, and needs to be further investigated.
Future studies will be undertaken to investigate the
mechanism(s) by which n-3 PUFA remodelled bioactive lipids
regulate metabolic pathways.
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